Synthetic lethality of p97 inhibition and PSMC2-overexpressionovercomes bortezomib resistance in multiple myeloma
James J Ignatz-Hoover, Ernest Ricky Chan, Ehsan Malek…·James Joseph Driscoll
This study identifies PSMC2 overexpression as a driver of bortezomib resistance in multiple myeloma and shows that combining p97 inhibition with bortezomib overcomes this resistance.